Date: 2013-10-02
Type of information: R&D agreement
Compound: XEN-D0103
Company: Servier (France) Xention (UK)
Therapeutic area: Cardiovascular diseases
Type agreement: R&D
development
commercialisation
Action mechanism: XEN-D0103 is a selective Kv1.5 modulator, a potassium channel expressed in the atria
Disease: atrial fibrillation
Details: * On October 2, 2013, Xention, a Cambridge-based biopharmaceutical company specialising in the discovery and development of ion channel-modulating drugs for atrial fibrillation, and the French pharmaceutical company Servier have entered into a multi-year agreement for the development and commercialisation of XEN-D0103, a selective Kv1.5 modulator discovered and developed by Xention for the treatment of atrial fibrillation.
Under the terms of the agreement, Servier has received an option to acquire certain intellectual property rights and to further develop and commercialise XEN-D0103 in all territories except the USA and Japan. All rights in the USA and Japan will be retained by Xention.
During the option period, the parties will undertake a joint programme of clinical development of XEN-D0103 undertaking two phase 2 clinical studies aimed at demonstrating the efficacy of XEN-D0103 in reducing AF burden in paroxysmal AF. When Servier exercises its option, it will be responsible for the further clinical development and commercialisation of XEN-D0103 within its territories.
Financial terms: In addition to an upfront fee, Servier will pay an option fee as well as a series of milestones totalling €120 million.
Latest news:
